If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

  • This share is currently suspended. It was suspended at a price of 440.00
  • There is currently no data for MRL

Form 8.3 - Marlowe PLC

30 Jul 2021 13:47

RNS Number : 1115H
Marlowe PLC
30 July 2021
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

Rule 8.3 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Alex Dacre

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

MARLOWE PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

30/07/2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ord

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

4,654,352

6.03%

 

 

(2) Cash-settled derivatives:

 

N/A

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

N/A

 

 

 

 

TOTAL:

4,654,352

6.03%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Ordinary shares of 50p

Details, including nature of the rights concerned and relevant percentages:

1. Marlowe plc Long Term Incentive Plan 2019 under which Alex Dacre has been granted 92,975 of new share options will vest, in whole or in part, on 1 April 2022 (or upon a change of control) subject to performance conditions involving the Company's compound annual total shareholder return having been met over the preceding three-year period.

 

Upon vesting, the options will be exercisable at a price of 50 pence per ordinary at any time prior to expiry on 31 March 2029.

 

2. Marlowe plc Long Term Incentive Plan 2020 under which Alex Dacre has been granted 63,380 of new share options will vest, in whole or in part, on 1 April 2023 (or upon a change of control) subject to performance conditions involving the Company's compound annual total shareholder return having been met over the preceding three-year period.

 

Upon vesting, the options will be exercisable at a price of 50 pence per ordinary at any time prior to expiry on 31 March 2030.

 

3. 3,913 share options vesting on 1 October 2023 under HMRC approved 2020 Save As You Earn scheme. Subject to the rules of the 2020 SAYE Scheme, participants will be able to exercise their 2020 SAYE Options within six-months commencing from 1 October 2023. The 2020 SAYE Options have an exercise price, calculated in accordance with the rules of the SAYE Scheme, of 460 pence per 2020 SAYE Option

 

4. Marlowe Executive Incentive Plan under which participants receive a 10% share of total shareholder return created above a hurdle of 10% per annum over a five year performance period. Growth in shareholder value is assessed from 1 April 2021 based on the number of issued Ordinary Shares of 50 pence each in the capital of the Company at that date and the March 2021 placing price of £6.90 per share.

 

Participants will receive a share of the pool created based on the proportion of the pool they are allocated. Alex Dacre has a 56.5% allocation.

 

The value of the pool will be converted into new shares at the end of the performance period in the form of a nil-cost options which can be exercised over a five year period from the date of grant (i.e. the end of the performance period), subject to a cap on the maximum number of shares which can be issued, equal to 4,902,295 new shares based on a dilution limit of 10% of the current share capital, less shares issued (and granted but not yet vested) for share incentive schemes since 2016.

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (£)

N/A

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

 

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

 

 

 

 

 

 

 

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

N/A

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

30/07/2021

Contact name:

Matthew Allen

Telephone number:

020 3813 8493

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETSDAFESEFSEDW
Date   Source Headline
1st Jul 20227:00 amRNSPublication of Annual Report
28th Jun 20227:00 amRNSFinal Results
23rd Jun 20227:00 amRNSNotice of Full Year Results Analyst Presentation
8th Jun 20227:00 amRNSAcquisition of HR Solutions
25th May 20227:00 amRNSAcquisition of Cedrec Information Systems Limited
23rd May 202212:55 pmRNSExercise of Share Options and Total Voting Rights
28th Apr 20224:22 pmRNSHolding(s) in Company
28th Apr 20224:18 pmRNSHolding(s) in Company
26th Apr 20224:36 pmRNSExercise of Share Options and Total Voting Rights
19th Apr 20227:00 amRNSAcquisition of TP Health
11th Apr 202210:47 amRNSExercise of Share Options
5th Apr 20223:05 pmRNSCapital Markets Day Replay
5th Apr 20227:00 amRNSCapital Markets Day
22nd Mar 20227:00 amRNSAcquisition of Griffin Fire
21st Mar 20227:00 amRNSNotice of Capital Markets Day and Trading Update
15th Mar 20227:00 amRNSAppointment of Joint Corporate Broker
17th Feb 20227:00 amRNSDirectorate Change
11th Feb 20227:00 amRNSAcquisition of S F Fire Limited
10th Feb 20227:00 amRNSNew Enlarged Debt Facility
31st Jan 202212:20 pmRNSHolding(s) in Company
28th Jan 20222:19 pmRNSDirector/PDMR Shareholding
27th Jan 20229:07 amRNSHolding(s) in Company
26th Jan 202211:39 amRNSDirector/PDMR Shareholding
26th Jan 20227:00 amRNSIssue of Equity and Total Voting Rights
21st Jan 20221:08 pmRNSHolding(s) in Company
20th Jan 20224:08 pmRNSResults of Placing
20th Jan 20227:48 amRNSProposed Placing and Acquisition of Optima Health
20th Jan 20227:00 amRNSAcquisition of Optima Health
19th Jan 202212:13 pmRNSAppointment of Independent Non-Executive Director
14th Jan 20225:01 pmRNSExercise of Share Options
20th Dec 20217:00 amRNSAcquisition of Skill Boosters
14th Dec 202111:12 amRNSHolding(s) in Company
1st Dec 20212:00 pmRNSHalf Year Results Presentation Replay
1st Dec 20217:00 amRNSHalf Year Results
24th Nov 20217:00 amRNSTrading Update and Notice of Results
5th Nov 20211:15 pmRNSDirectorate Change
20th Oct 20211:53 pmRNSResults of Placing and Director/PDMR Dealing
20th Oct 20217:00 amRNSAcquisition of EssentialSkillz & Proposed Placing
14th Oct 20217:00 amRNSRefinance and Acquisition Completion
13th Oct 20217:00 amRNSAppointment of Non-Executive Director
7th Oct 20217:00 amRNSAcquisition of Sterling Hydrotech
5th Oct 20217:00 amRNSFurther re CFO Appointment and Directorate Change
4th Oct 20217:00 amRNSAcquisitions of VinciWorks Legal & Hydro-X Group
15th Sep 20211:13 pmRNSResult of AGM
7th Sep 20217:00 amRNSAcquisition of Santia Limited
31st Aug 20217:00 amRNSLaunch of Group 2021 SAYE Scheme
18th Aug 20217:00 amRNSDirector Dealing, Equity Issue & Grant of Options
11th Aug 20213:20 pmRNSForm 8.3 - Marlowe Plc
11th Aug 202111:08 amRNSForm 8.5 (EPT/RI)
10th Aug 20212:34 pmRNSForm 8.3 - Marlowe plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.